Skip to main content
Equibles
JSPR logo

JSPR · Jasper Therapeutics, Inc. · Metrics

Track JSPR — free

Use JSPR with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research JSPR.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$0.54 +0.02 (+3.84%) At close · Oct 28
Rebalance outlook locked
Going-concern doubt — flagged Aug 14, 2026

Substantial doubt about the company's ability to continue as a going concern.

“Accordingly, based on the Company's current operating plan, and along with the Company's history of operating losses, and given the potential risk of having to repurchase the Non-Voting Convertible Preferred Stock if the Company is unable to obtain stockholder approval to convert it to Common Stock within 12 months, the Company's current cash and cash equivalents may not be sufficient to fund the Company's ongoing operations for a period of at least twelve months from the issuance date of these condensed consolidated financial statements. Accordingly, the Company has concluded that substantial doubt exists about its ability to continue as a going concern.”
View the 10-Q filed Aug 14, 2026
Market Cap
$17.27M
Shares
33.27M
Volume · Oct 28 371.17K Avg daily vol (3M) 495.2K

JSPR metrics

56 of 122 screener metrics currently available.

Open in screener

Market overview

2 metrics
Share price
$0.54
Market cap
$17.27M

Price action

20 metrics
Price change (1W)
+3.8%
Price change (30D)
-17.1%
Price change (3M)
-18.0%
Price change (6M)
-44.2%
Price change (YTD)
-71.6%
Price change (1Y)
-77.7%
Trailing year
Price change (5Y)
—
52-week high
$2.36
52-week low
$0.34
Change from 52-week high
-78.0%
Change from 52-week low
+52.2%
Annualized volatility
103.7%
Annualized volatility (3M)
86.0%
Beta
1.6
RSI (14D)
43.9
Price vs SMA 50
-15.5%
Price vs SMA 200
-40.2%
Avg volume (3M)
497,659
Relative volume
2.7
Average dollar volume
$330,393

Company

3 metrics
Sector
Healthcare
Industry
Biotechnology
Shares outstanding
33.27M

Valuation

12 metrics
P / E (TTM)
—
Trailing earnings
PEG ratio
—
EV / revenue
—
EV / EBITDA
—
EV / EBIT
—
P / sales
—
P / book
11.9
reciprocal yield 8.4%
FCF yield
—
TTM · current market cap
Buyback yield
—
P / FCF
—
P / operating cash flow
—
Earnings yield
-188.9%

Historical valuation

8 metrics
P / E historical average (3Y)
—
P / E historical average (5Y)
—
EV / revenue historical average (3Y)
—
EV / revenue historical average (5Y)
—
EV / EBIT historical average (3Y)
—
EV / EBIT historical average (5Y)
—
EV / EBITDA historical average (3Y)
—
EV / EBITDA historical average (5Y)
—

Dividends & buybacks

7 metrics
Dividend yield
—
Trailing 12 months
Payout ratio
—
Shareholder yield
—
Dividend / share (TTM)
—
Dividend growth YoY
—
Dividend growth streak
—
Last ex-dividend
—

Earnings calendar

2 metrics
Next earnings
—
Last earnings
2026-06-12

Profitability

9 metrics
Gross margin
—
Operating margin
—
Trailing 12 months
Net margin
—
Gross profit (TTM)
—
Operating profit (TTM)
−$55.16M
Net income (TTM)
−$31.77M
Trailing 12 months
Diluted EPS (TTM)
$-0.94
FCF margin
—
Effective tax rate
—

Per share

11 metrics
Revenue per diluted share (TTM)
—
Gross profit per diluted share (TTM)
—
Operating profit per diluted share (TTM)
—
EBITDA per diluted share (TTM)
—
Net income per diluted share (TTM)
—
Operating cash flow per diluted share (TTM)
—
Free cash flow per diluted share (TTM)
—
Capital expenditures per diluted share (TTM)
—
R&D per diluted share (TTM)
—
Stock compensation per diluted share (TTM)
—
Book value per share
$0.15

Growth

11 metrics
Revenue growth YoY
—
Year over year
Net income growth YoY
—
Revenue (TTM)
—
Trailing 12 months
EPS growth YoY
—
Shares change YoY
+87.1%
Year over year · more shares
Revenue CAGR (3Y)
—
Revenue CAGR (5Y)
—
EPS CAGR (3Y)
—
EPS CAGR (5Y)
—
FCF CAGR (3Y)
—
FCF CAGR (5Y)
—

Quality

14 metrics
Return on equity
-2,248.5%
Return on assets
-269.2%
Debt / equity
—
Current ratio
1.5
EBITDA (TTM)
—
Free cash flow (TTM)
—
Quick ratio
1.5
Interest coverage
—
Net debt / EBITDA
—
Return on invested capital
—
Trailing 12 months
Net cash
$7.31M
Latest balance sheet
Cash & equivalents
$7.31M
Total assets
$11.80M
Total debt
—

Cash flow & spend

7 metrics
Operating cash flow (TTM)
−$60.33M
Capital expenditures (TTM)
—
R&D (TTM)
$36.70M
SG&A (TTM)
—
Stock compensation (TTM)
$4.27M
R&D / revenue
—
Stock compensation / revenue
—

Ownership (13F)

9 metrics
13F filers
54
13F filer change QoQ
-10
Institutional ownership
46.0%
Conviction holders (share of 13F filers)
0.0%
Crowding (high-turnover and private-fund holders)
30.5%
Private-fund adviser ownership
29.3%
Active holders' share change QoQ
-18.9%
Holder tenure
9.1
Price vs estimated holder cost
-78.5%

Ownership (registered funds)

1 metrics
Index-fund ownership
4.3%

Short interest

3 metrics
Short interest
19.5%
Latest settlement · 18.5 days to cover
Days to cover
18.5d
Short-squeeze score
80 / 100

Insider activity

2 metrics
Net insider buying (90D)
—
Insider-sentiment score
—

Risk flags

1 metrics
Going concern
Flagged
Key facts CIK 1788028 CUSIP 471871202 13F (30d) 2 filings 2 filers Visit website Investor relations